Where to next with retinoids for cancer therapy?

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 2955-2957

  Smith, M A ^a   Anderson, B ^a  

^a CTEP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; BEXAROTENE; FENRETINIDE; ISOTRETINOIN; RETINOIC ACID; RETINOID;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; NEUROBLASTOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; HUMANS; ISOTRETINOIN; NEOPLASMS; RETINOIDS; TETRAHYDRONAPHTHALENES; TRETINOIN;

EID: 0034797691     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (43)

1. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer
2. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
3. A randomized comparison of all-trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
4. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
5. All-trans-retinoic acid in acute promyelocytic leukemia
6. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small cell lung cancer
7. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069
8. A phase I study of LGD1069 in adults with advanced cancer
9. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
10. 13-Cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the childrens cancer study group
11. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation
12. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy
13. Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
14. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)retinamide in neuroblastoma cell lines
15. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs
16. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms
17. Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamide-induced apoptosis
18. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors
19. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells
20. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma
21. Response of neuroblastoma cell lines to retinoic acid and 13-cis-retinoic, but not to fenretinide, is mediated by retinoic acid receptors
22. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells
23. Role of antioxidants and intracellular free radicals in retinamide-induced cell death
24. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism
25. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations
26. Phase I study of fenretinide in neuroblastoma
27. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437
28. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells
29. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3
30. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity
31. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells
32. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through upregulation of TRAIL receptors in human lung cancer cells
33. Chromatin remodeling and leukemia: New therapeutic paradigms
34. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
35. Initial clinical evaluation of "transcription therapy" for cancer: All-trans retinoic acid plus phenylbutyrate
36. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia
37. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro
38. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid
39. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice
40. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line
41. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines
42. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: Effects on the degradation of RARα and PML-RARα
43. Retinoid-induced differentiation of neuroblastoma: Comparison between LG69, an RXR-selective analogue and 9-cis retinoic acid